Cargrilintide (10 Vial Box)

Compliance & Disclaimer

• For Research Use Only
• Not FDA or EMA approved for clinical application
• Evidence is limited to preclinical studies; safety and efficacy in humans remain unestablished.

Cargrilintide is a long-acting amylin analog currently under investigation in preclinical and clinical research for its role in metabolic regulation. It is not approved for therapeutic use and is intended for laboratory research only. Existing data are derived from controlled trials and animal models; no claims of safety or efficacy in humans are made.

Mechanistic Insights

• Amylin Pathway Activation: Cargrilintide mimics endogenous amylin, a pancreatic hormone co-secreted with insulin, to slow gastric emptying, reduce glucagon secretion, and enhance satiety signaling.
• Calcitonin Receptor Engagement: Structural modifications enable interaction with calcitonin receptors, potentially influencing calcium homeostasis and metabolic signaling.
• Extended Half-Life: Lipidation and backbone modifications confer prolonged activity, supporting once-weekly dosing in research protocols.

Research Applications

• Obesity and Metabolic Disorders: Phase 2 and 3 trials report 8–11% weight reduction with monotherapy and up to 22.7% when combined with semaglutide (CagriSema) over 68 weeks.
• Glycemic Control: Combination therapy demonstrated HbA1c reductions of ~2.2%, outperforming monotherapy arms.
• Preclinical Findings: Rodent models suggest synergistic effects on appetite regulation and energy balance when paired with GLP-1 receptor agonists.

Key Peer-Reviewed References

• Kruse T. et al. Development of Cagrilintide, a Long-Acting Amylin Analog. J Med Chem. 2021;64(15):11183–11194. DOI:10.1021/acs.jmedchem.1c00565
• Mikhail N., Wali S. Cagrilintide Combined with Semaglutide: A New Approach for Obesity and Diabetes. Clin Trials Clin Res. 2023;2(5): DOI:10.31579/2834-5126/043
• Davies M.J. et al. Cagrilintide–Semaglutide in Adults with Obesity and Type 2 Diabetes. NEJM. 2025; DOI:NCT05394519